Maria Beumont‐Mauviel
Association Clinique et Thérapeutique Infantile du Val de Marne(FR)
Publications by Year
Research Areas
Hepatitis C virus research, Systemic Lupus Erythematosus Research, Chronic Lymphocytic Leukemia Research, HIV/AIDS drug development and treatment, Liver Disease Diagnosis and Treatment
Most-Cited Works
- → Simeprevir with pegylated interferon alfa 2a plus ribavirin in treatment-naive patients with chronic hepatitis C virus genotype 1 infection (QUEST-1): a phase 3, randomised, double-blind, placebo-controlled trial(2014)434 cited
- → Simeprevir with pegylated interferon alfa 2a or 2b plus ribavirin in treatment-naive patients with chronic hepatitis C virus genotype 1 infection (QUEST-2): a randomised, double-blind, placebo-controlled phase 3 trial(2014)373 cited
- → Once-daily simeprevir (TMC435) with pegylated interferon and ribavirin in treatment-naïve genotype 1 hepatitis C: The randomized PILLAR study(2013)270 cited
- → Simeprevir With Peginterferon and Ribavirin Leads to High Rates of SVR in Patients With HCV Genotype 1 Who Relapsed After Previous Therapy: A Phase 3 Trial(2014)254 cited
- → Simeprevir Increases Rate of Sustained Virologic Response Among Treatment-Experienced Patients With HCV Genotype-1 Infection: A Phase IIb Trial(2013)233 cited
- → Discovery and Development of Simeprevir (TMC435), a HCV NS3/4A Protease Inhibitor(2014)211 cited
- → 1413 SIMEPREVIR (TMC435) WITH PEGINTERFERON/RIBAVIRIN FOR TREATMENT OF CHRONIC HCV GENOTYPE-1 INFECTION IN TREATMENT-NAÏVE PATIENTS: RESULTS FROM QUEST-2, A PHASE III TRIAL(2013)121 cited
- → 1425 SIMEPREVIR (TMC435) WITH PEGINTERFERON/RIBAVIRIN FOR CHRONIC HCV GENOTYPE-1 INFECTION IN TREATMENT-NAÏVE PATIENTS: RESULTS FROM QUEST-1, A PHASE III TRIAL(2013)89 cited
- → Drug–Drug Interactions with the NS3/4A Protease Inhibitor Simeprevir(2015)77 cited
- → 10 RESULTS OF A PROOF OF CONCEPT STUDY (C210) OF TELAPREVIR MONOTHERAPY AND IN COMBINATION WITH PEGINTERFERON ALFA-2A AND RIBAVIRIN IN TREATMENT-NAIVE GENOTYPE 4 HCV PATIENTS(2009)57 cited